FDA said it is partnering with the European Medicines Agency (EMA) on regulatory strategies to facilitate the development of COVID-19 vaccines.

During a March 18 meeting, regulators discussed necessary preclinical data and the need to evaluate theoretical risk for vaccine-induced disease enhancement, while acknowledging the urgency of proceeding to human clinical trials with SARS-CoV-2 candidate vaccines

Related News Articles

Headline
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug…
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response yesterday awarded $600 million for 12 domestic COVID-19…
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
AHA is providing its latest social media toolkit to help hospitals encourage vaccination against COVID-19. The newest toolkit includes messages and assets…
Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…